Year: 2020

BERGENBIO ASA: Invitation to second quarter 2020 results webcast presentation

August 10, 2020

Bergen, Norway, 10 August 2020 – BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

UPDATE ON BEMCENTINIB’S INVOLVEMENT IN POTENTIAL TREATMENT OF COVID-19 PANDEMIC

July 28, 2020

BerGenBio in late stage set-up phase to sponsor and conduct a clinical study using bemcentinib…

Read More

BERGENBIO ANNOUNCES FIRST PATIENT DOSED IN RECURRENT GLIOBLASTOMA INVESTIGATOR SPONSORED PHASE I/II STUDY ASSESSING SELECTIVE AXL INHIBITOR BEMCENTINIB

July 20, 2020

Bergen, Norway, 20 July 2020 –BerGenBio ASA (OSE: BGBIO), a clinical-stage biopharmaceutical company developing novel,…

Read More

BERGENBIO ANNOUNCES POSITIVE interim CLINICAL AND TRANSlaTIONAL DATA from Phase II trial of BEMCENTINIB IN COMBINATION WITH KEYTRUDA® IN checkpoint inhibitor refractory NSCLC PATIENTS

June 25, 2020

6 of 7 checkpoint inhibitor refractory cAXL-positive patients report clinical benefit 12 evaluable patients for cAXL…

Read More

BERGENBIO ANNOUNCES CHANGE TO PRESENTATION TIME AT Next Gen Immuno-Oncology Congress

June 24, 2020

Bergen, Norway, 24 June 2020 – BerGenBio ASA (OSE:BGBIO), a clinical-stage biopharmaceutical company developing novel, selective…

Read More

BerGenBio to Present at the Upcoming Virtual European Biotech Investor Day 2020

June 23, 2020

Bergen, Norway, June 23, 2020 – BerGenBio, a clinical-stage biopharmaceutical company developing novel, selective AXL kinase inhibitors…

Read More